Association of serum procalcitonin level with in-stent restenosis in patients undergoing bare-metal stent implantation

Ornek E., Cetin M., Kiziltunc E., Kurtul A., Gok M., Kundi H.

BIOMARKERS IN MEDICINE, vol.12, no.5, pp.455-463, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 12 Issue: 5
  • Publication Date: 2018
  • Doi Number: 10.2217/bmm-2017-0242
  • Journal Name: BIOMARKERS IN MEDICINE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.455-463
  • Keywords: acute coronary syndrome, coronary bare-metal stent, inflammation, in-stent restenosis, procalcitonin, stable coronary artery disease, PERCUTANEOUS CORONARY INTERVENTION, ACUTE MYOCARDIAL-INFARCTION, C-REACTIVE PROTEIN, ARTERY-DISEASE, INFLAMMATION, METAANALYSIS, PREDICTOR, MARKER, INJURY
  • Gazi University Affiliated: No

Abstract

Aim: Procalcitonin (PCT) is an inflammatory marker and elevated PCT levels are associated with cardiovascular events. We assessed whether PCT level is an independent predictor of bare-metal stent (BMS) in-stent restenosis (ISR). Patients & methods: We evaluated 240 patients undergoing BMS implantation. Serum PCT levels were measured before procedure. Patients were classified as ISR(-) group (n = 120) and ISR(+) group (n = 120). Results: Serum PCT levels were higher in the ISR (+) group (p < 0.001). At multivariate analysis, PCT (odds ratio [OR] 1.561; p = 0.012), stent length (OR: 1.089), stent diameter (OR: 0.141) and uric acid (OR: 1.465) were independent predictors of ISR. Conclusion: Serum PCT is independently associated with ISR and increased PCT levels may provide useful information for the risk of BMS-ISR.